Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genzyme begins expansion of Boston manufacturing facility
Henri Termeer, chairman and CEO said: “The expansion of Allston Landing will help sustain the continued growth of Genzyme’s products. It will enable us to continue to fulfill
Henri Termeer, chairman and CEO said: “The expansion of Allston Landing will help sustain the continued growth of Genzyme’s products. It will enable us to continue to fulfill
Samaritan can now proceed with its proposed Phase II clinical study of Cushing’s syndrome SP-6300’s efficacy in patients experiencing hypercortisolism. Dr Janet Greeson, CEO, said: “We are extremely
In June, StemCells said that the four patents were pending reexamination by the US Patent and Trademark Office (PTO) based on petitions from Neuralstem. StemCells also noted defendants
The candidate, IPI-504, currently being evaluated in two separate multi-center clinical trials in patients with gastrointestinal stromal tumors (GIST) and other soft tissue sarcomas (STS), and in patients
The objective of the trial is to establish the maximum tolerated dose (MTD) and safety profile of Cloretazine (VNP40101M) in combination with Temodar (temozolomide) and then to study
Pursuant to the parties agreement, Sontra has acquired all of the outstanding shares of Echo common stock in exchange for an aggregate of 6.25 million shares of Sontra
The first cohort of six normal volunteers has been treated with single doses of G4544 without experiencing significant side effects. G4544 is a new tablet formulation that enables
Tridural is a first-line therapy for adult patients with moderate pain who require treatment for several days or more that provides 24-hour pain relief from a single tablet
This latest approval is based on results of a double-blind, randomized clinical trial involving 1,109 patients with either complicated urinary tract infections (cUTI) or acute pyelonephritis (AP) which
Asubio will use this data to supplement its current filing to the Japanese Ministry of Health, Labour and Welfare for approval of its BH4 product for the treatment